September 12, 2011

Lyxumia® (lixisenatide) One-Step Regimen as Effective as Two-Step Regimen in Improving Glycemic Control in Type 2 Diabetes

- New phase III data from GetGoal-F1 study of once-daily lixisenatide support simplified treatment initiation -
- Study results presented at the European Association for the Study of Diabetes (EASD) 47th Annual Meeting -

 

Lyxumia® (lixisenatide) One-Step Regimen as Effective as Two-Step Regimen in Improving Glycemic Control in Type 2 Diabetes
- New phase III data from GetGoal-F1 study of once-daily lixisenatide support simplified treatment initiation -
- Study results presented at the European Association for the Study of Diabetes (EASD) 47th Annual Meeting -

Paris, France – September 12, 2011 – Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that Lyxumia® (lixisenatide), a once-daily GLP-1 receptor agonist under development for type 2 diabetes, achieved its primary efficacy endpoint of significant HbA1c reduction vs. placebo in patients uncontrolled on metformin. The study objectives were to compare the efficacy and safety of lixisenatide versus placebo in one-step and two-step dose increase regimens in terms of reduction in HbA1c.